Trump seeks to slash $6 billion from government medical research: why not more? | |
(To read about Jon's mega-collection, Exit From The Matrix, click here.)
|
|
Trump seeks to slash $6 billion from gov't medical research: why not more?
By Jon Rappoport
The US National Institutes of Health (NIH), a federal agency, is the largest medical research institution in the world.
Its 2010 budget was $30 billion. It employs 20,000 people.
Here's what you need to know: no one has ever done a
comprehensive investigation of the results of NIH's research over the
years. No one has done a proper assessment of its value.
If NIH were a corporation, it would have undergone numerous
assessments of its products. But government work is different. There are
no standards. "We're trying our best" is good enough. Especially when
in-house PR flacks with media connections trumpet "breakthroughs" and
"upcoming innovations right around the corner."
Back in 1987, I interviewed Jim Warner, a White House policy
analyst in the Reagan administration. Warner told me he had to pull rank
to even get through and talk to scientists at NIH.
"These guys [at NIH] assume that it's their show. They just
assume it," he said. He was referring to the then-current research on
AIDS.
I suggested that someone should do an overall investigation
of NIH, to see how valuable its research had proved to be over the past
20 years. He agreed. He said he hadn't thought of that, and it was a
good idea.
Of course, it never happened.
The situation at NIH is preposterous. If you owned a company
that made parts for planes, wouldn't you do quality control? Wouldn't
you want to know how well those plane parts were performing in the real
world?
Let's take one area, out of the 27 separate NIH centers that
do medical research: NCI, the National Cancer Institute. How is the War
on Cancer going?
From The Skeptical Inquirer, Jan.-Feb. 2010, author Reynold Spector:
"...Gina Kolata pointed out in The New York
Times [2009] that the cancer death rate, adjusted for the size and age
of the population, has decreased by only 5 percent since 1950...She
argues that there has been very little overall progress in the war on
cancer."
Author Spector points out how researchers can manipulate
results to create the impression that cancer treatment is becoming more
successful: "...there are several types of detection bias. First, if one
discovers a malignant tumor very early and starts therapy immediately,
even if the therapy is worthless, it will appear that the patient lives
longer than a second patient (with an identical tumor) treated with
another worthless drug if the cancer in the second patient was detected
later. Second, detection bias can also occur with small tumors,
especially of the breast and prostate, that would not harm the patient
if left untreated but can lead to unnecessary and sometimes mutilating
therapy."
Spector discusses prostate cancer: "...prostate cancer
therapy also presents a serious quandary. At autopsy, approximately 30
percent (or more) of men have cancer foci in their prostate glands, yet
only 1 to 2 percent of men die of prostate cancer. Thus less than 10
percent of prostate cancer patients require treatment. This presents a
serious dilemma: whom should the physician treat? Moreover, recently,
two large studies of prostate cancer screening with prostate specific
antigen (PSA) have seriously questioned the utility of screening. In one
study, the investigators had to screen over a thousand men before they
saved one life. This led to about fifty "false positive" patients who
often underwent surgery and/or radiation therapy unnecessarily (Schröder
et al. 2009). The second study, conducted in the United States, was
negative (Andriole et al. 2009), i.e., no lives were saved due to the
screening, but many of the screening-positive patients with prostate
cancer were treated. Welch and Albertson (2009) and Brawley (2009)
estimate that more than a million men in the U.S. have been
unnecessarily treated for prostate cancer between 1986 and 2005, due to
over-diagnostic PSA screening tests. In the end, screening for prostate
cancer will not be useful until methods are developed to determine which
prostate cancers detected by screening will harm the patient (Welch and
Albertson 2009; Brawley 2009)."
What about so-called smart drugs for cancer? Spector: "Smart
drugs are defined as drugs that focus on a particular vulnerability of
the cancer; they are not generalized but rather specific toxins. But the
Journal of the American Medical Association (Health
Agencies Update 2009) reports that 90 percent of the drugs or biologics
approved by the FDA in the past four years for cancer (many of them
smart drugs) cost more than $20,000 for twelve weeks of therapy, and
many offer a survival benefit of only two months or less (Fojo and Grady
2009)."
Spector cites an example of such a smart drug: "The FDA has
approved bevacizumab...Since the median survival of colorectal cancer is
eighteen months, bevacizumab therapy would cost about $144,000 (in such
a patient) for four months prolongation of survival (Keim
2008)...Moreover, bevacizumab can have terrible side effects, including
gastrointestinal perforations, serious bleeding, severe hypertension,
clot formation, and delayed wound healing (PDR 2009)...bevacizumab is at
best a marginal drug. It only slightly prolongs life, demonstrable only
in colorectal cancer, has serious side effects, and is very expensive."
Cancer research at NIH is plunging ahead, of course. If we
could be sure these scientists are on the right track, and their
failures and shortcomings are wholly owing to the fact that cancer is
such a tough problem, then perhaps they should be funded for their
ongoing work.
But that is not the case.
The scientists themselves tell us they're on the right track. That is the only assurance we have.
I'm fully aware of much cancer research that has taken place
outside the mainstream over the past hundred years. In this article, I'm
not exploring those efforts. I'm making the point that NIH is flying
without navigation tools and pretending they are pre-eminent princes.
WITH NO COMPREHENSIVE ASSESSMENT OF THE VALUE OF NIH'S WORK FOR THE PAST
50 YEARS---we are not looking at science.
We are looking at an unaccountable boondoggle---and the brutal effects of conventional treatment.
Trump wants to slash $6 billion from the NIH budget? That's a start.
But a truly sane approach would result in shutting the place
down with NO funds for research, until a truly independent body figures
out what the hell has been going on there.
As a reporter who has been investigating deep medical fraud
and harm for the past 30 years, I can assure you the scandals that would
slither out of deep corners at NIH would fry the brains of the average
American.
Just one example: leading researchers, in the mid-1980s, took
a failed, highly toxic, chemo drug called AZT off their dusty shelves
and decided it was their best shot at treating AIDS. AZT attacks all
cells of the body. It decimates bone marrow, where cells of the immune
system are manufactured. And this drug became the treatment for AIDS,
whose hallmark was: depletion of the immune system. AZT was the medical
version of Vietnam: "We had to destroy the village in order to save
it..."
|
|
| |
Use this link to order Jon's Matrix Collections.
|
|
| |
Jon Rappoport
The
author of three explosive collections, THE MATRIX REVEALED, EXIT FROM
THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US
Congressional seat in the 29th District of California. He maintains a
consulting practice for private clients, the purpose of which is the
expansion of personal creative power. Nominated for a Pulitzer Prize, he
has worked as an investigative reporter for 30 years, writing articles
on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin
Magazine, Stern, and other newspapers and magazines in the US and
Europe. Jon has delivered lectures and seminars on global politics,
health, logic, and creative power to audiences around the world.
|
|
| |
You can find this article and more at NoMoreFakeNews.com.
|
No comments:
Post a Comment